Publications – Center for Communicable Disease Dynamics

Mass drug administration of azithromycin: an analysis.

Author(s): Kahn R, Eyal N, Sow SO, Lipsitch MJournal: Clin Microbiol InfectPMID: 36309328 October 2022

The World Health Organization recommends mass drug administration (MDA) of the antibiotic azithromycin for children 1-11 months of age in areas…

How to test SARS-CoV-2 vaccines ethically even after one is available.

Author(s): Eyal N, Lipsitch MJournal: Clin Infect DisPMID: 33639622 February 2021

Although vaccines against SARS-CoV-2 have now been found safe and efficacious, there remains an urgent global health need to test…

Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure.

Author(s): Eyal N, Lipsitch MJournal: Clin Microbiol InfectPMID: 33421580 January 2021

A vaccine trial with a conventional challenge design can be very fast once it starts, but it requires a long…

Reply to Hasford and to Spinola et al.

Author(s): Eyal N, Lipsitch M, Smith PGJournal: J Infect DisPMID: 32845306 August 2020

We proposed human challenge trials (HCTs) as a possible alternative or complement to conventional phase 3 trials for expedited severe…

Opinion: It’s ethical to test promising coronavirus vaccines against less-promising ones.

Author(s): Eyal N, Lipsitch MJournal: Proc Natl Acad Sci U S APMID: 32699147 July 2020

With multiple candidate vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entering efficacy testing, researchers and ethicists should come…

Response to Cioffi.

Author(s): Eyal N, Lipsitch M, Smith PGJournal: J Infect DisPMID: 32348499 June 2020

Dr Cioffi rails against our comparison of human challenge studies to organ donation, but the risk of donor death from…

Response to Dawson et al.

Author(s): Eyal N, Lipsitch M, Smith PGJournal: J Infect DisPMID: 32495823 June 2020

Dawson et al raise three concerns about human challenge trials to assess the efficacy of SARS-CoV-2 vaccines. First, that current…

Human challenge studies to accelerate coronavirus vaccine licensure.

Author(s): Eyal N, Lipsitch M, Smith PGJournal: J Infect DisPMID: 32232474 May 2020

Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing…

Regulating impact on bystanders in clinical trials: An unsettled frontier.

Author(s): Eyal N, Kimmelman J, Holtzman LG, Lipsitch MJournal: Clin TrialsPMID: 31368813 August 2019

This article informally reviews key research ethics guidelines and regulations, academic scholarship, and research studies and finds wide variety in…

Opinion: Risk to study nonparticipants: A procedural approach.

Author(s): Eyal N, Lipsitch M, Bärnighausen T, Wikler DJournal: Proc Natl Acad Sci U S APMID: 30087210 August 2018